Letter
Who will fund hypothesis testing studies?
Cite this as:
BMJ
2006;332:666.4
- Mira Harrison-Woolrych, director (Mira.harrison-woolrych@stonebow.otago.ac.nz)
- Intensive Medicines Monitoring Programme, University of Otago, Dunedin, New Zealand
EDITOR—Although Loke et al concluded that case reports in pharmacovigilance have limited value,1 case reports or series are valuable as hypothesis generating papers, which benefit clinicians and patients. The number of follow-up studies is only one outcome by which to judge the value of case reports or series, but other outcomes may be more difficult to study.
Although case …
Sign in
Personal subscribers, sign in here:
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
CiteULike
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
Re: How much of a social media profile can doctors have?
Published 13 February 2012
Re: Diagnosis and management of Raynaud’s phenomenon
Published 13 February 2012
Re: Is it unethical for doctors to encourage healthy adults to donate a kidney to a stranger? No
Published 13 February 2012
Re: Report predicts 20 million AIDS orphans in Africa by 2010
Published 13 February 2012
Re: On the impossibility of being expert
Published 13 February 2012
Most responses
Does anyone understand the government’s plan for the NHS? (17 responses)
Published 17 Jan 2012
Bad medicine: medical nutrition (15 responses)
Published 18 Jan 2012
Shared decision making: really putting patients at the centre of healthcare (8 responses)
Published 27 Jan 2012
How much of a social media profile can doctors have? (7 responses)
Published 23 Jan 2012
Why legislation is necessary for my health reforms (7 responses)
Published 1 Feb 2012